On Friday, Barclays downgraded its recommendation on Eurofins Scientific from 'overweight' to 'weighted in line', with a price target reduced from 65 to 50 euros, which now shows only a 4% upside potential.

At the current price, the stock has a 2024 P/E of just over 20 times, with a yield of over 1%.

Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.